Literature DB >> 4199714

Consequences of smallpox vaccination in leprosy patients.

K Saha, M M Mittal, S N Ray.   

Abstract

This study illustrates the consequences of smallpox revaccination in 45 lepromatous, 28 tuberculoid, and 47 normal individuals. Results obtained with intradermal inoculations indicated that the patients with leprosy were associated with a relative anergy against the vaccinia virus, the anergy being minimal in the tuberculoid leprosy but marked in the cases with lepromatous leprosy. Major vaccinial reactions were observed more often in patients with lepromatous leprosy than in the controls or patients with tuberculoid leprosy. Furthermore in a patient with lepromatous leprosy, vaccinia necrosum also developed. The smallpox vaccination with live virus also appeared as a provocative factor for the precipitation of lepra reaction in the lepromatous leprosy cases. After 3 weeks of vaccination, the frequency of the specific humoral antibody response was the same in the tuberculoid patients and controls while it was higher in the cases with lepromatous leprosy. The prevaccination titer of total hemagglutination inhibition antibody was significantly higher in the lepromatous leprosy cases. However, the postvaccinial, humoral antibody response of the lepromatous patients was of the same magnitude as that observed in the normal individuals, and it was mainly due to a 2-mercaptoethanol-resistant antibody.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4199714      PMCID: PMC422848          DOI: 10.1128/iai.8.3.301-308.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

Review 1.  Immunization against smallpox.

Authors:  C Kaplan
Journal:  Br Med Bull       Date:  1969-05       Impact factor: 4.291

2.  A study of cell mediated immunity in leprosy: changing trends in the immunological spectrum of the disease.

Authors:  K Saha; M M Mittal
Journal:  Clin Exp Immunol       Date:  1971-06       Impact factor: 4.330

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Status of humoral immune responses in leprosy.

Authors:  P Jha; K Balakrishnan; G P Talwar; L K Bhutani
Journal:  Int J Lepr Other Mycobact Dis       Date:  1971 Jan-Mar

Review 5.  Cell-mediated immune responses to virus infections and virus-induced tumours.

Authors:  A C Allison
Journal:  Br Med Bull       Date:  1967-01       Impact factor: 4.291

6.  Timing of different virus neutralizing 19S and 7S antibodies in natural coxsackie infections of newborn babies and adults.

Authors:  O Mäkelä; K Lapinleimu; E Kostiainen
Journal:  Clin Exp Immunol       Date:  1968-03       Impact factor: 4.330

7.  Immunological aspects of clinical leprosy.

Authors:  J Turk
Journal:  Proc R Soc Med       Date:  1970-10

8.  Inactivated smallpox vaccine. A comparison of inactivation methods.

Authors:  G S Turner; E J Squires; H G Murray
Journal:  J Hyg (Lond)       Date:  1970-06

9.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

10.  Immunological aspects of leprosy with special reference to autoimmune diseases.

Authors:  O Wager
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  3 in total

1.  Antibody-mediated immunity in CFW mice infected with Mycobacterium lepraemurium. Humoral immune response in murine leprosy.

Authors:  O Rojas-Espinosa; M Casoluengo-Méndez; G V Díaz
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

Review 2.  Possible immunosuppressive effects of drug exposure and environmental and nutritional effects on infection and vaccination.

Authors:  H P Huemer
Journal:  Mediators Inflamm       Date:  2015-04-05       Impact factor: 4.711

3.  Erythema nodosum leprosum post-COVID-19 vaccination: endemic while pandemic.

Authors:  T Fachler; K Olshtain-Pops; L Horev
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-08       Impact factor: 9.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.